123 related articles for article (PubMed ID: 32631510)
61. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
62. Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties.
Fang JK; Xu Z; Zhang Y; Zhang W; Liu B; Fang Y; Sun T
Anticancer Agents Med Chem; 2016; 16(12):1665-1672. PubMed ID: 27349449
[TBL] [Abstract][Full Text] [Related]
63. Design, Synthesis and Biological Evaluation of Benzohydrazide Derivatives Containing Dihydropyrazoles as Potential EGFR Kinase Inhibitors.
Wang HC; Yan XQ; Yan TL; Li HX; Wang ZC; Zhu HL
Molecules; 2016 Aug; 21(8):. PubMed ID: 27527130
[TBL] [Abstract][Full Text] [Related]
64. 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).
Chan S; Han K; Qu R; Tong L; Li Y; Zhang Z; Cheng H; Lu X; Patterson A; Smaill J; Ren X; Ding J; Xie H; Ding K
Bioorg Med Chem Lett; 2015 Oct; 25(19):4277-81. PubMed ID: 26259806
[TBL] [Abstract][Full Text] [Related]
65. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
[TBL] [Abstract][Full Text] [Related]
66. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
[TBL] [Abstract][Full Text] [Related]
67. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
[TBL] [Abstract][Full Text] [Related]
68. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
Sabbah DA; Hajjo R; Sweidan K
Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
[TBL] [Abstract][Full Text] [Related]
69. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
Ghorab MM; Alsaid MS; Soliman AM; Al-Mishari AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):67-73. PubMed ID: 29098904
[TBL] [Abstract][Full Text] [Related]
70. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
[TBL] [Abstract][Full Text] [Related]
71. Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors.
Wang XR; Wang S; Li WB; Xu KY; Qiao XP; Jing XL; Wang ZX; Yang CJ; Chen SW
Eur J Med Chem; 2021 Mar; 213():113192. PubMed ID: 33493829
[TBL] [Abstract][Full Text] [Related]
72. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.
Soliman AM; Alqahtani AS; Ghorab M
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303
[TBL] [Abstract][Full Text] [Related]
73. Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Wang X; Zhang T; Sun D; Tong Y; Xu Y; Chen H; Tong L; Zhu L; Zhao Z; Chen Z; Ding J; Xie H; Xu Y; Li H
J Med Chem; 2016 Aug; 59(15):7111-24. PubMed ID: 27396610
[TBL] [Abstract][Full Text] [Related]
74. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
75. New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies.
Koh EJ; El-Gamal MI; Oh CH; Lee SH; Sim T; Kim G; Choi HS; Hong JH; Lee SG; Yoo KH
Eur J Med Chem; 2013; 70():10-21. PubMed ID: 24128410
[TBL] [Abstract][Full Text] [Related]
76. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
77. Design and synthesis of selective degraders of EGFR
Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K
Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162
[TBL] [Abstract][Full Text] [Related]
78. Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents.
Abbas HS; Abd El-Karim SS
Bioorg Chem; 2019 Aug; 89():103035. PubMed ID: 31200286
[TBL] [Abstract][Full Text] [Related]
79. Discovery of a potent dual ALK and EGFR T790M inhibitor.
Jang J; Son JB; To C; Bahcall M; Kim SY; Kang SY; Mushajiang M; Lee Y; Jänne PA; Choi HG; Gray NS
Eur J Med Chem; 2017 Aug; 136():497-510. PubMed ID: 28528303
[TBL] [Abstract][Full Text] [Related]
80. Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549).
Coyne CP; Narayanan L
Anticancer Agents Med Chem; 2019; 19(6):802-819. PubMed ID: 30514195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]